SWOG Biospecimen Bank

SWOG 生物样本库

• 批准号: 9252983
• 负责人: Julie M Gastier-Foster
• 金额: $ 277.71万
• 依托单位: RESEARCH INST NATIONWIDE CHILDREN'S HOSP
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-04-23 至 2020-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9252983
• 关键词: Address; Adult; Breast; Cancer Patient; Clinical; Clinical Data; Clinical Medicine; Clinical Research; Clinical Treatment; Clinical Trials; Clinical Trials Information for Patients; Clinical trial protocol document; Collection; Colon; Component of the National Cancer Institute; Data; Development; Diagnostic; Disease; Enrollment; Ensure; Epidemiology; Guidelines; Health; Human; Laboratories; Link; Lung; Lymphoma; Malignant Neoplasms; Molecular Biology; Molecular Profiling; Multiple Myeloma; National Cancer Institute; National Clinical Trials Network; Operative Surgical Procedures; Pathologic; Patient Care; Patients; Pediatric Hospitals; Procedures; Process; Prostate; Protocols documentation; Reporting; Research; Research Infrastructure; Research Personnel; Residual state; Resources; Sampling; Services; Southwest Oncology Group; Specimen; Therapeutic; Translational Research; Treatment Protocols; Tumor Bank; Work; anticancer research; base; biobank; cancer clinical trial; cancer therapy; cancer type; design; follow-up; innovative technologies; laboratory equipment; leukemia; melanoma; programs; public health relevance; translational medicine; treatment trial; tumor

 DESCRIPTION (provided by applicant): SWOG is an adult clinical trials cancer group within the National Clinical Trials Network (NCTN) of the National Cancer Institute (NCI). SWOG clinical trials include a range of cancer types (e.g., breast, lung, colon, prostate, leukemia, melanoma, lymphoma, and multiple myeloma). The SWOG Biospecimen Bank (SWOG BB), located in the Biopathology Center at Nationwide Children's Hospital, was designed to procure, process, bank, and distribute biospecimens collected as a major component of NCI sponsored clinical treatment trials. These biospecimens are linked to demographic data, surgical and pathological reports, treatment information, and follow-up data. These biospecimens, upon review and approval, are prioritized for distribution to the specific SWOG investigators defined in the clinical trial protocols. Once those needs have been addressed, residual (legacy) banked biospecimens can be distributed to other approved investigators within and outside SWOG. The Bank is a functioning and viable part of SWOG's clinical and translational medicine program, and focuses on the integration of diagnostic, therapeutic, laboratory, and clinical data to answer questions in clinical and translational research. The SWOG BB works under the hypothesis that banking of high quality, clinically-annotated and cancer-related human biospecimens, linked to molecular signatures/markers, will significantly facilitate clinical cancer research. To support ths effort, the SWOG BB manages these biospecimens using standard operating procedures based on current best practices for biorepositories and the latest laboratory technology. As a result the Bank is able to maintain an accurate and effective resource of tumor and normal samples with associated clinical, epidemiologic, and protected health information. The Bank promotes research by qualified investigators by providing access to the Biospecimen IT Navigator and the NCTN "front door" services. The SWOG BB aims to harmonize and expand general banking practices and innovative technologies facilitating molecular biology research and increase investigator participation in clinical research trials via the NCI sponsored Group Banking Committee (GBC). The SWOG BB also proposes to expand its infrastructure to support the banking, processing, and distribution of biospecimens from patients with cancer participating in NCI ETCTN Clinical Trials.

 描述（由申请人提供）：SWOG是美国国家癌症研究所（NCI）国家临床试验网络（NCTN）内的成人临床试验癌症组。SWOG临床试验包括一系列癌症类型（例如，乳腺、肺、结肠、前列腺、白血病、黑素瘤、淋巴瘤和多发性骨髓瘤）。SWOG生物标本库（SWOG BB）位于全国儿童医院的生物病理学中心，旨在采购、处理、储存和分发作为NCI申办的临床治疗试验的主要组成部分收集的生物标本。这些生物样本与人口统计数据、手术和病理报告、治疗信息和随访数据相关联。这些生物标本经审查和批准后，优先分发给 临床试验方案一旦这些需求得到解决，剩余（遗留）库存生物标本可以分发给SWOG内外的其他经批准的研究者。该银行是SWOG临床和转化医学计划的一个功能和可行的部分，并专注于诊断，治疗，实验室和临床数据的整合，以回答临床和转化研究中的问题。SWOG BB的工作假设是，与分子特征/标志物相关的高质量、临床注释和癌症相关的人类生物标本库将显著促进临床癌症研究。为了支持这项工作，SWOG BB使用基于当前生物储存库最佳实践和最新实验室技术的标准操作程序管理这些生物标本。结果是 库能够保持准确有效的肿瘤和正常样本资源，以及相关的临床、流行病学和受保护的健康信息。世界银行通过提供生物样本信息技术导航和国家技术中心网络“前门”服务，促进合格的研究人员进行研究。SWOG BB旨在通过NCI赞助的集团银行委员会（GBC）协调和扩展一般银行实践和创新技术，促进分子生物学研究，并增加研究者对临床研究试验的参与。SWOG BB还建议扩大其基础设施，以支持参与NCI ETCTN临床试验的癌症患者的生物标本的储存、处理和分发。